Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 5
Submit an article Journal homepage
454
Views
4
CrossRef citations to date
0
Altmetric
Special Report

Pharmacogenetics of Opiates in Clinical Practice: the Visible Tip of the Iceberg

Aline Hajj1 Laboratoire de Pharmacologie Clinique et Pharmacocinétique, Faculté de Pharmacie, Université Saint Joseph, Beyrouth, Liban, LebanonView further author information
,
Lydia Khabbaz1 Laboratoire de Pharmacologie Clinique et Pharmacocinétique, Faculté de Pharmacie, Université Saint Joseph, Beyrouth, Liban, LebanonView further author information
,
Jean-Louis Laplanche2 Service de Biochimie et de Biologie moléculaire, Hôpital Lariboisière, AP-HP, Paris, France;3 INSERMU705/UMR8206 & Laboratoire de Biologie Cellulaire, UniversityParis Descartes, 6 Avenue de l‘Observatoire,75006Paris, yFranceView further author information
&
Katell Peoc‘h2 Service de Biochimie et de Biologie moléculaire, Hôpital Lariboisière, AP-HP, Paris, France;3 INSERMU705/UMR8206 & Laboratoire de Biologie Cellulaire, UniversityParis Descartes, 6 Avenue de l‘Observatoire,75006Paris, yFranceCorrespondence[email protected]
View further author information
Pages 575-585 | Published online: 05 Apr 2013

References

  • Mague SD , BlendyJA. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend.108(3) , 172–182 (2010).
  • Kreek MJ , BartG, LillyC, LaForgeKS, NielsenDA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol. Rev.57(1) , 1–26 (2005).
  • Droney J , RileyJ. Recent advances in the use of opioids for cancer pain. J. Pain Res.2 , 135–155 (2009).
  • Wu CL , RajaSN. Treatment of acute postoperative pain. Lancet377(9784) , 2215–2225 (2011).
  • Butler B , RubinG, LawranceA, BateyR, BellJ. Estimating the risk of fatal arrhythmia in patients in methadone maintenance treatment for heroin addiction. Drug Alcohol Rev.30(2) , 173–180 (2011).
  • Angst MS , PhillipsNG, DroverDR et al. Opioid pharmaco using a twin study paradigm: methods and procedures for determining familial aggregation and heritability. Twin Res. Hum. Genet. 13(5) , 412–425 (2010).
  • Matthes HW , MaldonadoR, SimoninF et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383(6603) , 819–823 (1996).
  • Shabalina SA , ZaykinDV, GrisP et al. Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum. Mol. Genet. 18(6) , 1037–1051 (2009).
  • Goodman L , BruntonLL, ChabnerB, KnollmannBC. Goodman & Gilman‘s the Pharmacological Basis of Therapeutics (12th Edition). McGraw–Hill Medical, NY, USA (2012).
  • Ravindranathan A , JoslynG, RobertsonM, SchuckitMA, WhistlerJL, WhiteRL. Functional characterization of human variants of the mu-opioid receptor gene. Proc. Natl Acad. Sci. USA106(26) , 10811–10816 (2009).
  • Bond C , LaForgeKS, TianM et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95(16) , 9608–9613 (1998).
  • Zhang Y , WangD, JohnsonAD, PappAC, SadeeW. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem.280(38) , 32618–32624 (2005).
  • Niemi G , BreivikH. Epinephrine markedly improves thoracic epidural analgesia produced by a small-dose infusion of ropivacaine, fentanyl, and epinephrine after major thoracic or abdominal surgery: a randomized, double-blinded crossover study with and without epinephrine. Anesth. Analg.94(6) , 1598–1605 (2002).
  • Raja SN , ChoiY, AsanoY, HolmesC, GoldsteinDS. Arteriovenous differences in plasma concentrations of catechols in rats with neuropathic pain. Anesthesiology83(5) , 1000–1008 (1995).
  • Rakvag TT , KlepstadP, BaarC et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116(1–2) , 73–78 (2005).
  • Lachman HM , PapolosDF, SaitoT, YuYM, SzumlanskiCL, WeinshilboumRM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics6(3) , 243–250 (1996).
  • Oneda B , CrettolS, BochudM et al. β-arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J. 11(4) , 258–266 (2011).
  • Klein U , MullerC, ChuP, BirnbaumerM, von Zastrow M. Heterologous inhibition of G protein-coupled receptor endocytosis mediated by receptor-specific trafficking of β-arrestins. J. Biol. Chem.276(20) , 17442–17447 (2001).
  • Kang M , MagumaHT, SmithTH, RossGR, DeweyWL, AkbaraliHI. The role of β-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract. J. Pharmacol. Exp. Ther.340(3) , 567–576 (2012).
  • Lötsch J , PrussH, VehRW, DoehringA. A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenet. Genomics20(5) , 291–297 (2010).
  • Bouer R , BartheL, PhilibertC, TournaireC, WoodleyJ, HouinG. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam. Clin. Pharmacol.13(4) , 494–500 (1999).
  • Mashayekhi SO , SattariMR, RoutledgePA. Evidence of active transport involvement in morphine transport via MDCKII and MDCKPGP cell lines. Res. Pharm. Sci.5(2) , 99–106 (2010).
  • Tournier N , ChevillardL, MegarbaneB, PirnayS, ScherrmannJM, DeclevesX. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int. J. Neuropsychopharmacol.13(7) , 905–915 (2010).
  • Wandel C , KimR, WoodM, WoodA. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology96(4) , 913–920 (2002).
  • Hoffmeyer S , BurkO, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97(7) , 3473–3478 (2000).
  • Wang D , JohnsonAD, PappAC, KroetzDL, SadeeW. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics15(10) , 693–704 (2005).
  • Osborne R , JoelS, TrewD, SlevinM. Analgesic activity of morphine-6-glucuronide. Lancet1(8589) , 828 (1988).
  • Smith MT . Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin. Exp. Pharmacol. Physiol.27(7) , 524–528 (2000).
  • Eichelbaum M , EvertB. Influence of pharmacogenetics on drug disposition and response. Clin. Exp. Pharmacol. Physiol.23(10–11) , 983–985 (1996).
  • Lamba JK , LinYS, SchuetzEG, ThummelKE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. (2012).
  • Totah RA , SheffelsP, RobertsT, WhittingtonD, ThummelK, KharaschED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology108(3) , 363–374 (2008).
  • Walter C , LötschJ. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain146(3) , 270–275 (2009).
  • Finco G , PintorM, SannaD et al. Is target opioid therapy within sight? Minerva Anestesiol. 78(4) , 462–472 (2012).
  • Tammimaki A , MannistoPT. Catechol-O-methyltransferase gene polymorphism and chronic human pain: a systematic review and meta-analysis. Pharmacogenet. Genomics22(9) , 673–691 (2012).
  • Reyes-Gibby CC , SheteS, RakvagT et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130(1–2) , 25–30 (2007).
  • Rakvag TT , RossJR, SatoH, SkorpenF, KaasaS, KlepstadP. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol. Pain4 , 64 (2008).
  • Zubieta JK , HeitzegMM, SmithYR et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science299(5610) , 1240–1243 (2003).
  • Ross JR , RileyJ, TaegetmeyerAB et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance1 gene polymorphisms are associated with central side effects. Cancer 112(6) , 1390–1403 (2008).
  • Kim H , MittalDP, IadarolaMJ, DionneRA. Genetic predictors for acute experimental cold and heat pain sensitivity in humans. J. Med. Genet.43(8) , e40 (2006).
  • Campa D , GioiaA, TomeiA, PoliP, BaraleR. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther.83(4) , 559–566 (2008).
  • Meineke I , FreudenthalerS, HofmannU et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br. J. Clin. Pharmacol. 54(6) , 592–603 (2002).
  • Lötsch J , von Hentig N, Freynhagen R et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet. Genomics19(6) , 429–436 (2009).
  • Klepstad P , FladvadT, SkorpenF et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 152(5) , 1139–1145 (2011).
  • Sawyer MB , InnocentiF, DasS et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin. Pharmacol. Ther. 73(6) , 566–574 (2003).
  • Holthe M , KlepstadP, ZahlsenK et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur. J. Clin. Pharmacol. 58(5) , 353–356 (2002).
  • Coulbault L , BeaussierM, VerstuyftC et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. 79(4) , 316–324 (2006).
  • Holthe M , RakvagTN, KlepstadP et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 3(1) , 17–26 (2003).
  • Darbari DS , van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am. J. Hematol.83(3) , 200–202 (2008).
  • Nishizawa D , NagashimaM, KatohR et al. Association between KCNJ6 (GIRK2) gene polymorphisms and postoperative analgesic requirements after major abdominal surgery. PLoS ONE 4(9) , e7060 (2009).
  • Henker RA , LewisA, DaiF et al. The associations between OPRM1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation. Biol. Res. Nurs. doi:10.1177/1099800411436171 (2012) (Epub ahead of print).
  • Ross JR , RutterD, WelshK et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 5(5) , 324–336 (2005).
  • Laugsand EA , FladvadT, SkorpenF et al. Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids. Eur. J. Cancer 47(11) , 1682–1691 (2011).
  • Fujita K , AndoY, YamamotoW et al. Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother. Pharmacol. 65(2) , 251–258 (2011).
  • Romberg RR , OlofsenE, BijlH et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102(3) , 522–530 (2005).
  • Eap CB , BuclinT, BaumannP. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet.41(14) , 1153–1193 (2002).
  • Crettol S , DeglonJJ, BessonJ et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther.80(6) , 668–681 (2006).
  • Eap CB , CrettolS, RougierJS et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin. Pharmacol. Ther. 81(5) , 719–728 (2007).
  • Elkader AK , BrandsB, DunnE, SelbyP, SprouleBA. Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. J. Clin. Psychopharmacol.29(1) , 77–81 (2009).
  • Lötsch J , SkarkeC, WietingJ et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin. Pharmacol. Ther. 79(1) , 72–89 (2006).
  • Oneda B , CrettolS, Jaquenoud Sirot E, Bochud M, Ansermot N, Eap CB. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet. Genomics19(11) , 877–883 (2009).
  • Coller JK , BarrattDT, DahlenK, LoennechenMH, SomogyiAA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin. Pharmacol. Ther.80(6) , 682–690 (2006).
  • Levran O , O‘HaraK, PelesE et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum. Mol. Genet.17(14) , 2219–2227 (2008).
  • Iribarne C , BerthouF, BairdS et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 9(2) , 365–373 (1996).
  • Eap CB , BrolyF, MinoA et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J. Clin. Psychopharmacol. 21(2) , 229–234 (2001).
  • Gerber JG , RhodesRJ, GalJ. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality16(1) , 36–44 (2004).
  • Crettol S , DeglonJJ, BessonJ et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78(6) , 593–604 (2005).
  • Fonseca F , de la Torre R, Diaz L et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS ONE6(5) , e19527 (2011).
  • Levran O , PelesE, HamonS, RandesiM, AdelsonM, KreekMJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict. Biol. doi:10.1111/j.1369-1600.2011.00349.x (2011) (Epub ahead of print).
  • De Bels D , StaroukineM, DevriendtJ. Torsades de pointes due to methadone. Ann. Intern. Med.139(2) , e156 (2003).
  • Lin C , SombergT, MolnarJ, SombergJ. The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology113(1) , 59–65 (2009).
  • Wang SC , TsouHH, ChenCH et al. Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients. Eur. Neuropsychopharmacol. 22(10) , 695–703 (2012).
  • Mignat C , WilleU, ZieglerA. Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci.56(10) , 793–799 (1995).
  • Volpe DA , McMahon Tobin GA, Mellon RD et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul. Toxicol. Pharmacol.59(3) , 385–390 (2011).
  • Crews KR , GaedigkA, DunnenbergerHM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91(2) , 321–326 (2012).
  • Koren G , CairnsJ, ChitayatD, GaedigkA, LeederSJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet368(9536) , 704 (2006).
  • Madadi P , RossCJ, HaydenMR et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case–control study. Clin. Pharmacol. Ther. 85(1) , 31–35 (2009).
  • Levo A , KoskiA, OjanperaI, VuoriE, SajantilaA. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci. Int.135(1) , 9–15 (2003).
  • Stamer UM , StuberF, MudersT, MusshoffF. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth. Analg.107(3) , 926–929 (2008).
  • Coluzzi F , MattiaC. Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol.71(7–8) , 451–460 (2005).
  • Lalovic B , KharaschE, HofferC, RislerL, Liu-ChenLY, ShenDD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin. Pharmacol. Ther.79(5) , 461–479 (2006).
  • Kalso E . How different is oxycodone from morphine? Pain132(3) , 227–228 (2007).
  • Andreassen TN , EftedalI, KlepstadP et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur. J. Clin. Pharmacol. 68(1) , 55–64 (2012).
  • Samer CF , DaaliY, WagnerM et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br. J. Pharmacol. 160(4) , 919–930 (2010).
  • Jannetto PJ , WongSH, GockSB, Laleli-SahinE, SchurBC, JentzenJM. Pharmaco as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. J. Anal. Toxicol.26(7) , 438–447 (2002).
  • Madadi P , HildebrandtD, GongIY et al. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics 126(4) , e986–e989 (2010).
  • Anton RF , OrosziG, O‘MalleyS et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 65(2) , 135–144 (2008).
  • Kim SG , KimCM, ChoiSW et al. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl.) 201(4) , 611–618 (2009).
  • Oslin DW , BerrettiniW, KranzlerHR et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28(8) , 1546–1552 (2003).
  • Ray LA , CourtneyKE, BujarskiS, SquegliaLM. Pharmacogenetics of alcoholism: a clinical neuroscience perspective. Pharmacogenomics13(2) , 129–132 (2012).
  • Lötsch J , GeisslingerG. Pharmacogenetics of new analgesics. Br. J. Pharmacol.163(3) , 447–460 (2011).
  • Klepstad P , RakvagTT, KaasaS et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 48(10) , 1232–1239 (2004).
  • Chou WY , YangLC, LuHF et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol. Scand. 50(7) , 787–792 (2006).
  • Sia AT , LimY, LimEC et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 109(3) , 520–526 (2008).
  • Hayashida M , NagashimaM, SatohY et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 9(11) , 1605–1616 (2008).
  • Huehne K , LeisS, MuensterT et al. High post surgical opioid requirements in Crohn‘s disease are not due to a general change in pain sensitivity. Eur. J. Pain 13(10) , 1036–1042 (2009).
  • Kolesnikov Y , GabovitsB, LevinA, VoikoE, VeskeA. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. Anesth. Analg.112(2) , 448–453 (2011).
  • Shinderman M , MaxwellS, Brawand-AmeyM, GolayKP, BaumannP, EapCB. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend.69(2) , 205–211 (2003).
  • Lötsch J , GeisslingerG. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J.6(3) , 200–210 (2006).
  • Wang SC , HoIK, TsouHH et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone Senantiomer. J. Clin. Psychopharmacol.31(4) , 463–469 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.